X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs CADILA HEALTHCARE - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA CADILA HEALTHCARE DISHMAN PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 25.1 16.8 149.4% View Chart
P/BV x 3.3 4.0 84.1% View Chart
Dividend Yield % 0.7 1.0 64.5%  

Financials

 DISHMAN PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
CADILA HEALTHCARE
Mar-18
DISHMAN PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs374558 67.1%   
Low Rs129362 35.7%   
Sales per share (Unadj.) Rs197.8116.3 170.1%  
Earnings per share (Unadj.) Rs21.217.9 118.7%  
Cash flow per share (Unadj.) Rs34.723.1 150.1%  
Dividends per share (Unadj.) Rs2.003.50 57.1%  
Dividend yield (eoy) %0.80.8 104.4%  
Book value per share (Unadj.) Rs179.985.4 210.6%  
Shares outstanding (eoy) m80.691,023.74 7.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.0 32.2%   
Avg P/E ratio x11.925.7 46.1%  
P/CF ratio (eoy) x7.219.9 36.5%  
Price / Book Value ratio x1.45.4 26.0%  
Dividend payout %9.419.6 48.1%   
Avg Mkt Cap Rs m20,306470,664 4.3%   
No. of employees `0000.811.8 7.0%   
Total wages/salary Rs m5,35518,545 28.9%   
Avg. sales/employee Rs Th19,252.710,072.7 191.1%   
Avg. wages/employee Rs Th6,459.51,569.1 411.7%   
Avg. net profit/employee Rs Th2,064.11,547.7 133.4%   
INCOME DATA
Net Sales Rs m15,961119,049 13.4%  
Other income Rs m2651,132 23.4%   
Total revenues Rs m16,226120,181 13.5%   
Gross profit Rs m4,10328,475 14.4%  
Depreciation Rs m1,0915,388 20.2%   
Interest Rs m944911 103.7%   
Profit before tax Rs m2,33423,308 10.0%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6245,644 11.0%   
Profit after tax Rs m1,71118,292 9.4%  
Gross profit margin %25.723.9 107.5%  
Effective tax rate %26.724.2 110.4%   
Net profit margin %10.715.4 69.8%  
BALANCE SHEET DATA
Current assets Rs m11,01882,005 13.4%   
Current liabilities Rs m9,51760,720 15.7%   
Net working cap to sales %9.417.9 52.6%  
Current ratio x1.21.4 85.7%  
Inventory Days Days11073 151.1%  
Debtors Days Days3598 35.4%  
Net fixed assets Rs m16,30483,703 19.5%   
Share capital Rs m1611,024 15.8%   
"Free" reserves Rs m12,90786,421 14.9%   
Net worth Rs m14,51687,445 16.6%   
Long term debt Rs m4,18925,551 16.4%   
Total assets Rs m29,805180,653 16.5%  
Interest coverage x3.526.6 13.1%   
Debt to equity ratio x0.30.3 98.8%  
Sales to assets ratio x0.50.7 81.3%   
Return on assets %8.910.6 83.8%  
Return on equity %11.820.9 56.4%  
Return on capital %17.522.0 79.7%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95242,683 11.6%   
Fx outflow Rs m69711,242 6.2%   
Net fx Rs m4,25531,441 13.5%   
CASH FLOW
From Operations Rs m2,7869,193 30.3%  
From Investments Rs m-1,529-9,737 15.7%  
From Financial Activity Rs m-941515 -182.7%  
Net Cashflow Rs m316-29 -1,091.0%  

Share Holding

Indian Promoters % 61.4 74.8 82.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 8.3 44.6%  
FIIs % 12.7 5.9 215.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 11.0 200.9%  
Shareholders   46,261 44,069 105.0%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - STRIDES SHASUN LTD COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS